What Clinical Trial Decision Makers Are Prioritizing In 2025

In 2025, clinical trial operations are undergoing a transformative shift driven by the need for speed, cost-efficiency, and patient-centered approaches. Based on insights from over 100 experienced U.S.-based biotech and pharma leaders in clinical operations, this report uncovers the top priorities shaping the future of trials. Efficiency emerged as the foremost concern, with 73% of respondents citing it as critical to success amid increasing trial complexity and decentralized models. Real World Evidence (RWE) followed closely, prioritized by 56% of leaders seeking to support regulatory decisions and long-term safety evaluations. Patient retention, noted by 49%, is also gaining traction, especially in chronic or long-duration studies.

These leaders, averaging 12 years of experience, wield significant influence over vendor decisions, with 59% actively sourcing new solutions. The findings highlight a strong appetite for innovation in operational design, data strategy, and patient engagement. Clinical stakeholders that embrace agile processes, integrate real-world data, and invest in participant retention are better positioned to meet 2025’s demanding trial landscape.